Skip to main content
OpenTrials
Completed

NCT Number: NCT04001634

Dual Anti-HER2 Therapy (Lapatinib and Trastuzumab) Plus Chemotherapy in HER2-positive MBC

To explore the real world situation of trastuzumab and lapatinib combined chemotherapy in China, and to explore the relationship between progression free survival and treatment.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Breast Cancer Breast Diseases Breast Neoplasms Neoplasms Neoplasms by Site Skin Diseases Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

Female

Study type

Observational

Primary location

Biyun Wang, MD

Shanghai, Shanghai Municipality, 200032, China

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 1. woman, age > 18 years old 2. Diagnosed with HER2 +Metastatic Breast Cancer 3. Dual anti-HER2 therapy (lapatinib and trastuzumab) plus chemotherapy for at least one cycle, starting from 2013.09.01-2019.07.31 4. Available medical history

Exclusion criteria

  • 1. Incomplete medical history

Treatment and study plan

Primary outcomes

  1. PFS

    Time frame: 6 weeks

    Progression free survival

  2. OS

    Time frame: 6 weeks

    Overall survival

  3. ORR

    Time frame: 6 weeks

    Objective Response Rate

Secondary outcomes

  1. Treatment Pattern

    Time frame: 6 weeks

    Choice of Treatment

Sponsors and collaborators

Lead sponsor

Fudan University

Other

Registry information

Official study title

Dual Anti-HER2 Therapy (Lapatinib and Trastuzumab) Plus Chemotherapy in Metastatic HER2-positive Breast Cancer Patients- a Multicenter Retrospective Study

Important dates

Study start
2015
Primary completion
2019
Study completion
2020
First posted
Jun 28, 2019
Registry last updated
Feb 26, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.